How have SNPX shares performed in 2024?

Synaptogenix's stock was trading at $6.7975 on January 1st, 2024. Since then, SNPX stock has decreased by 36.3% and is now trading at $4.33. View the best growth stocks for 2024 here .

Are investors shorting Synaptogenix?

Synaptogenix saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 11,900 shares, a decrease of 97.2% from the March 15th total of 426,600 shares. Based on an average daily volume of 40,800 shares, the short-interest ratio is presently 0.3 days. Currently, 1.1% of the company's stock are short sold. View Synaptogenix's Short Interest .

When is Synaptogenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SNPX earnings forecast .

When did Synaptogenix's stock split?

Synaptogenix shares reverse split on Friday, April 5th 2024. The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Synaptogenix?

Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SNPX

Synaptogenix (SNPX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free SNPX Stock Alerts

$4.33

-0.33 (-7.08%)

(As of 04/19/2024 ET)

Compare

Today's Range: $4.25
▼
$4.71
50-Day Range: $3.97
▼
$6.64
52-Week Range: $3.53
▼
$47.00

Volume: 29,861 shs
Average Volume: 43,953 shs
Market Capitalization: $4.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Synaptogenix alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Synaptogenix Stock (NASDAQ:SNPX)

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

SNPX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNPX Stock News Headlines

April 5, 2024 | uk.investing.com

Synaptogenix announces reverse stock split to regain Nasdaq compliance

April 4, 2024 | msn.com

What's Going On With Synaptogenix (SNPX) Stock?

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 3, 2024 | finance.yahoo.com

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

February 22, 2024 | msn.com

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%

December 19, 2023 | finance.yahoo.com

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

December 6, 2023 | finance.yahoo.com

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

November 2, 2023 | finance.yahoo.com

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

September 26, 2023 | finance.yahoo.com

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

September 7, 2023 | finance.yahoo.com

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

July 19, 2023 | prnewswire.com

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

July 14, 2023 | benzinga.com

Short Volatility Alert: Synaptogenix Inc

July 13, 2023 | benzinga.com

Synaptogenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%

July 13, 2023 | marketwatch.com

Synaptogenix Shares Rise 48% After Alzheimer's Drug Abstract Accepted at Conference

July 13, 2023 | finance.yahoo.com

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

June 24, 2023 | finance.yahoo.com

SNPX - Synaptogenix, Inc.

March 7, 2023 | finance.yahoo.com

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

February 27, 2023 | reuters.com

SNPX.O

December 20, 2022 | msn.com

Peering Into Synaptogenix's Recent Short Interest

December 16, 2022 | seekingalpha.com

Synaptogenix crashes 69% as Phase 2 trial for Alzheimer’s candidate fails

December 16, 2022 | finance.yahoo.com

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

December 9, 2022 | seekingalpha.com

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

November 18, 2022 | seekingalpha.com

Synaptogenix announces $15M private placement with existing investors

November 18, 2022 | finance.yahoo.com

Synaptogenix Announces $15 Million Private Placement with Existing Investors

October 22, 2022 | ca.finance.yahoo.com

Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

October 19, 2022 | finance.yahoo.com

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

See More Headlines

Receive SNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SNPX
CUSIP: N/A
CIK: 1571934
Web: www.synaptogen.com
Phone: 973-242-0005
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($26.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,040,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -22.50%
Return on Assets: -18.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.14
Quick Ratio: 7.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $25.27 per share
Price / Book: 0.18

Miscellaneous

Outstanding Shares: 1,090,000
Free Float: 1,038,000
Market Cap: $4.92 million
Optionable: Not Optionable
Beta: 1.33

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Alan J. Tuchman M.D. (Age 77)
MBA(FAAN), CEO & Director
Comp: $303.35k
Dr. Daniel L. Alkon M.D. (Age 82)
President, Chief Scientific Officer & Director
Comp: $375k
Mr. Robert Weinstein (Age 64)
CFO, Executive VP, Treasurer & Secretary
Comp: $568.92k

Key Competitors

View All Competitors

SNPX Stock Analysis - Frequently Asked Questions

How have SNPX shares performed in 2024?: Synaptogenix's stock was trading at $6.7975 on January 1st, 2024. Since then, SNPX stock has decreased by 36.3% and is now trading at $4.33.
View the best growth stocks for 2024 here.
Are investors shorting Synaptogenix?: Synaptogenix saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 11,900 shares, a decrease of 97.2% from the March 15th total of 426,600 shares. Based on an average daily volume of 40,800 shares, the short-interest ratio is presently 0.3 days. Currently, 1.1% of the company's stock are short sold.
View Synaptogenix's Short Interest.
When is Synaptogenix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SNPX earnings forecast.

When did Synaptogenix's stock split?: Synaptogenix shares reverse split on Friday, April 5th 2024. The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
How do I buy shares of Synaptogenix?: Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNPX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Synaptogenix (SNPX) Stock Price, News & Analysis

About Synaptogenix Stock (NASDAQ:SNPX)

SNPX Stock Price History

SNPX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

SNPX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info